Your search for non small cell lung cancer returned 48 results

Researchers say they have identified adverse events that are more likely to occur in cancer patients receiving antibody-drug conjugates.

The decision to withdraw Exkivity was made after the confirmatory trial failed to meet the primary endpoint.

Patients from racial and ethnic minority groups are still underrepresented in cancer research, despite efforts to make clinical trials more diverse.

Cancer patients with biomarker-positive tumors have better outcomes on immune checkpoint inhibitor therapy, a meta-analysis suggests.

Improvement seen compared with chemotherapy alone for first-line treatment of advanced non-small cell lung cancer.

The designation is supported by data from the ongoing phase 2 KEYNOTE-942 study, which included 157 patients with stage III/IV melanoma following complete resection.

Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse

Is lung cancer screening using risk-based low-dose computer tomography a better predictor of lung cancer risk than age or pack/years of smoking?

The sBLA was supported by data from the phase 3 TOPAZ-1 trial.

Sintilimab is an investigational programmed death receptor-1 (PD-1) inhibitor.